METHOD FOR NON-SPECIFIC PREVENTION OF ACUTE RESPIRATORY INFECTIONS IN INFANTS WITH CHRONIC HERPETIC INFECTIONS - CYTOMEGALOVIRUS, EPSTEIN-BARR VIRUS Russian patent published in 2021 - IPC A61K38/21 A61P31/12 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pediatrics, infectious diseases, and concerns a method for non-specific prevention of acute respiratory infections in infants with chronic herpetic infections - cytomegalovirus, Epstein-Barr virus. The method includes using an antiviral preparation and is characterised by the fact that interferon alfa-2b - genferon-light is administered to patients in 125000 mg suppositories, 1 suppository 2 times a day three times a week for one month in combination with administration of a water solution of vitamin 25(OH) D for one month, wherein prior to the beginning of the course of prophylaxis, the level of 25(OH) - vitamin D is determined in the blood serum, and if the level of vitamin D is <10 ng/ml - the dose of the preparation is 4000 IU/day; from 11 to 20 ng/ml - the dose of the preparation is 3000 IU/day; 21 to 29 ng/ml - dose of the preparation is 2000 IU/day; >30 ng/ml - the dose of the preparation is 1500 IU/day for 1 month; the observation regime is performed for 6 months. After the end of the course of administration of interferon alpha-2b and vitamin D, the level of quantitative content of cytomegalovirus (CMV), Epstein-Barr virus (EBV) in blood and saliva is monitored by polymerase chain reaction (PCR) and the serum level content of vitamin 25 (OH) D is determined. In case of negative data of the polymerase chain reaction to cytomegalovirus and Epstein-Barr virus in the blood, preservation of viruses in saliva up to 1500 copies/ml in the absence of clinical manifestations and indicators of vitamin 25 (OH) D within the normal range, the course of prophylaxis is completed; in case of a deviation from said indicators from the standard, the course of prophylaxis is continued up to 6 months.

EFFECT: invention allows reducing the frequency, duration, severity of the course of newly emerging acute respiratory infections against the background of herpetic pathology; reducing the quantitative indicator of viral activity of cytomegalovirus and Epstein-Barr virus in PCR of blood and saliva, improving the course of the infectious process, transferring from the aggravation process to a state of stable remission; restoring the level of vitamin D to an optimal value in order to normalise the immune response and increasing local reactivity of the mucous membranes of the nasopharynx.

1 cl, 3 tbl, 4 ex